Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) PT at $13.75

Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $13.75.

RVNC has been the topic of a number of research analyst reports. Barclays cut their price target on shares of Revance Therapeutics from $35.00 to $10.00 and set an "overweight" rating on the stock in a report on Monday, January 29th. Needham & Company LLC cut their price target on shares of Revance Therapeutics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 29th. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Revance Therapeutics in a report on Thursday, February 29th. The Goldman Sachs Group boosted their price target on shares of Revance Therapeutics from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Friday, March 1st. Finally, Piper Sandler cut their price target on shares of Revance Therapeutics from $42.00 to $20.00 and set an "overweight" rating on the stock in a report on Thursday, February 29th.

Revance Therapeutics Stock Performance

RVNC traded down $0.19 during mid-day trading on Monday, reaching $4.73. 1,111,547 shares of the stock were exchanged, compared to its average volume of 1,828,598. The stock has a market capitalization of $492.96 million, a PE ratio of -1.24 and a beta of 1.06. The company has a 50 day moving average price of $5.60 and a two-hundred day moving average price of $7.62. Revance Therapeutics has a 1 year low of $4.57 and a 1 year high of $37.98.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.17. The firm had revenue of $69.80 million for the quarter, compared to analysts' expectations of $64.02 million. Sell-side analysts expect that Revance Therapeutics will post -2.17 EPS for the current fiscal year.

Insider Activity

In other news, President Dustin S. Sjuts sold 9,211 shares of the company's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $5.04, for a total transaction of $46,423.44. Following the sale, the president now directly owns 167,550 shares in the company, valued at $844,452. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Dwight Moxie sold 8,125 shares of the company's stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $5.04, for a total value of $40,950.00. Following the transaction, the insider now directly owns 137,815 shares in the company, valued at $694,587.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Dustin S. Sjuts sold 9,211 shares of the company's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total transaction of $46,423.44. Following the completion of the transaction, the president now owns 167,550 shares in the company, valued at $844,452. The disclosure for this sale can be found here. Insiders have sold a total of 26,697 shares of company stock worth $134,553 over the last ninety days. Company insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. HighPoint Advisor Group LLC bought a new position in shares of Revance Therapeutics in the fourth quarter worth approximately $98,000. Vanguard Group Inc. boosted its stake in Revance Therapeutics by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 5,069,625 shares of the biopharmaceutical company's stock worth $44,562,000 after buying an additional 278,166 shares in the last quarter. American International Group Inc. boosted its stake in Revance Therapeutics by 4.5% in the fourth quarter. American International Group Inc. now owns 43,497 shares of the biopharmaceutical company's stock worth $382,000 after buying an additional 1,863 shares in the last quarter. Sierra Summit Advisors LLC purchased a new stake in Revance Therapeutics in the fourth quarter worth approximately $760,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Revance Therapeutics by 6.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 53,865 shares of the biopharmaceutical company's stock worth $474,000 after buying an additional 3,487 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.